Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.

被引：0
|
作者：
Zhang, Nan
Li, Jiongyuan
Piao, Mingjian
Li, Chengjie
Xun, Ziyu
Zhang, Longhao
Wang, Yanyu
Liu, Kai
Wang, Shanshan
Wang, Hanping
Zhao, Hai-Tao
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
[2] Peking Union Med Coll & Chinese Acad Med Sci, Div Pulm & Crit Care Med, State Key Lab Severe & Rare Dis, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16169
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).
    Fan, Jia
    Qin, Shukui
    Sun, Hui-Chuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS628 - TPS628
  • [33] Cetuximab plus mFOLFOX-6 as first-line therapy for unresectable liver metastases from colorectal cancer: an open-label, non-randomized, multicenter phase II clinical trial (CLIME Study)
    Cai, S.
    Zhang, W. E. N.
    Li, W.
    Xu, Y.
    Gu, W.
    Guan, Z.
    Cai, J. Q.
    Song, C.
    Xu, J. M.
    Chi, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S541 - S541
  • [34] Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.
    Li, Jinpeng
    Chen, Hua
    Song, Jinlong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma
    Micha, John P.
    Rettenmaier, Mark A.
    Bohart, Randy D.
    Goldstein, Bram H.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (02)
  • [36] Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study)
    Kuang, Ming
    Xu, Lixia
    Zhang, Mengping
    Zheng, Gaomin
    Zhang, Chuankai
    Zhang, Ying
    Su, Tianhong
    Wang, Jifei
    Wang, Fang
    Wang, Fengjie
    Chen, Huanwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Sintilimab combined sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase II study.
    Wang, Jiabei
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16182 - E16182
  • [38] Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
    Sun, J.
    Enzinger, P.
    Adenis, A.
    Shah, M.
    Kato, K.
    Bennouna, J.
    Doi, T.
    Hawk, N.
    Yu, L.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S352 - S352
  • [39] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subject with unresectable hepatocellular carcinoma.
    Finn, Richard S.
    Cheng, Ann-Lii
    Ikeda, Kenji
    Kudo, Masatoshi
    Tamai, Toshiyuki
    Dutcus, Corina E.
    Younger, Steven
    Han, Kwang-Hyub
    Qin, Shukui
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345